Proteostasis Therapeutics, Inc. Announces Extension Of Funded Collaboration With Cystic Fibrosis Foundation Therapeutics, Inc. For Novel Therapies Targeting Most Common CF Mutation
Published: Mar 04, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced an extension of its funded collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to research, develop and commercialize therapeutic candidates to treat people with cystic fibrosis (CF) who have the most common CF mutation, ?F508del. This extension will focus on moving the Company’s lead compounds toward a development candidate this year and a goal of filing an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration in 2015.
Help employers find you! Check out all the jobs and post your resume.